|Dr. Maxine Gowen||CEO, Pres & Exec. Director||784.52k||N/A||1958|
|Mr. John M. Limongelli||Chief Admin. Officer, Sr. VP, Gen. Counsel & Corp. Sec.||457.48k||N/A||1970|
|Dr. Howard A. Rockman M.D.||Scientific Founder, Consultant and Member of Scientific Advisory Board||N/A||N/A||N/A|
|Dr. Jonathan Violin Ph.D.||Sr. VP of Scientific Affairs & Investor Relations Officer||N/A||N/A||1975|
|Mr. Roberto E. Cuca||CFO, Sr. VP, Treasurer & Principal Accounting Officer||N/A||N/A||1968|
Trevena, Inc., a biopharmaceutical company, develops therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. Its product candidates include OLINVO injection, a G protein biased ligand of the µ opioid receptor that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is preferred; TRV250, a G protein biased ligand targeting the d-receptor, which is in Phase I clinical study for the treatment of migraine; and TRV734, a small molecule G protein biased ligand of the µ opioid receptor that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain, as well as TRV027 for the treatment of acute heart failure. The company was founded in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Trevena, Inc.’s ISS Governance QualityScore as of April 1, 2018 is 6. The pillar scores are Audit: 2; Board: 2; Shareholder Rights: 8; Compensation: 9.